Early recognition of cardiac sarcoidosis (CS) is important to initiate early treatment and prevent heart failure and sudden cardiac death. However, diagnosis of CS can be challenging and requires a high-index of suspicion. Cardiac magnetic resonance imaging (CMR) and 18F-fluorodeoxyglucose PET (18F FDG PET) have opened new avenues in the detection of CS. Experience with hybrid PET/MRI at our institution demonstrates improved workflow, decreased patient radiation exposure (compared to PET/CT) and incremental diagnostic value in imaging of CS. Both modalities are complementary, and offer important diagnostic and prognostic clinical data.